Home » Topics » Disease categories and therapies » Endocrine/metabolic

Endocrine/metabolic
RSS

Novartis and Osiris Therapeutics to codevelop bone and cartilage disease therapies

June 18, 1997

First clinical trials results reported for leptin

June 18, 1997

Zonagen reports results of second phase III trial of Vasomax

June 17, 1997

New vial size of generic leucovorin approved by FDA

June 17, 1997

Vitamin E for maternal diabetes-associated malformations in offspring

June 16, 1997

Neurogen reports promising phase I results with antiobesity drug

June 13, 1997

Osiris and Activated Cell Therapy initiate MSC collaboration

June 13, 1997

Testosterone transdermal patch now available in the U.S. in a once-daily formulation

June 13, 1997

Combination insulin sensitizer + alpha-glucosidase inhibitor for diabetes

June 13, 1997

Fibrinogen antagonists in IDDM

June 13, 1997

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for July 13, 2026.
FENS 2026: Next-gen biologics take on brain disease
BioWorld
Whether by fine-tuning neurotransmitter signaling or silencing disease-associated genes, emerging biologic therapies are reshaping neuroscience drug development,...
Ionis, AZ shares down on unexpected Wainua flop in cardiomyopathy
BioWorld
News of the unexpected phase III failure of the gene silencing drug Wainua (eplontersen) in the treatment of transthyretin-mediated amyloid cardiomyopathy sent...
Neurovalens granted FDA approval for PTSD therapy for US veterans
BioWorld
Veterans in the U.S. suffering from post-traumatic stress disorder (PTSD) now have access to Neurovalens Ltd.’s Modius Spero, a wearable neuromodulation device,...
NRF2 activators reported in Vailima Peninsula patent
BioWorld Science
Vailima Peninsula Pty Ltd. has discovered new nuclear factor erythroid 2-related factor 2 (NFE2L2; NRF2) activators potentially useful for the treatment of...